Jeff Hansen
| This email address is being protected from spambots. You need JavaScript enabled to view it.Research Editor
jeffhans@uab.edu | (205) 209-2355Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.
Specific beats:
- Alabama Drug Discovery Alliance
- Biochemistry and Molecular Genetics
- Biomatrix Engineering and Regenerative Medicine
- Cell biology
- Center for Biophysical Sciences and Engineering
- CCTS
- Center for Metabolic Bone Disease
- Microbiology
- Neurobiology
- Comprehensive Neuroscience Center
- Pathology, research shared with MS2
- Pharmacology and Toxicology
- Physiology and Biophysics
- UAB Research Foundation/IIE
- Research Administration
Experiments reveal that a catalytic subunit of CK2, called CK2α, is an important regulator of mouse CD8+ T cell activation, metabolic reprogramming and differentiation, both in vitro and in a mouse-infection model by the intracellular pathogen Listeria monocytogenes.
Direct reprogramming is a potential therapy for heart attack patients. In vitro, TBX20 improved contractility and mitochondrial function of reprogrammed heart muscle cells.
Diseases linked to atherosclerosis are the leading cause of death in the United States.
This novel finding will help guide successful therapeutic design and strategies for acute kidney injury and chronic kidney disease.
Knockout of TXNIP improves diabetes-associated hyperglycemia and hyperglucagonemia.
The clinically approved drug ruxolitinib suppressed a mouse model of melanoma that is resistant to immune checkpoint blockers.
Noninvasive ventilation is possible in infants at limits of viability. But unlike in slightly older preterm infants, noninvasive ventilation did not show an advantage in infants of 22 weeks-0 days to 23 weeks-6 days gestational age.
Zhang wins $11.2 million NIH PPG grant to improve heart attack recovery through growth of new heart muscle cells.
The deciphering of a new signaling cascade sheds light on how mutations in metabolism cause normal cells to become cancerous.
A novel activity against hypothiocyanite has been found for an E. coli enzyme and homologs enzymes in Streptococcus, Staphylococcus and Bacteroides species, with implications for diseases like cystic fibrosis and inflammatory bowel disease.